Skip to main content

Table 1 Odds ratios for breast cancer incidence by VEGF genotype.

From: Polymorphisms in the vascular endothelial growth factor gene and breast cancer in the Cancer Prevention Study II cohort

Polymorphism

Controls (n = 504)

All casesa (n = 501)

In situ cases (n = 107)

Invasive cases (n = 380)

 

n (%)

n (%)

OR (95% CI)

n (%)

OR (95% CI)

n (%)

OR (95% CI)

-2578C/A (rs 699947)

   AA

130 (26.3 %)

114 (22.9%)

1.00 (ref.)

31 (29.0 %)

1.00 (ref.)

81 (21.4 %)

1.00 (ref.)

   AC

236 (47.7%)

245 (49.2%)

1.18 (0.86–1.61)

53 (49.5%)

0.92 (0.55–1.52)

184 (48.7%)

1.24 (0.88–1.74)

   CC

129 (26.1%)

139 (27.9%)

1.25 (0.88–1.77)

23 (21.5%)

0.68 (0.37–1.24)

113 (29.9%)

1.46 (1.00–2.14)

   P (for trend)

  

0.21

 

0.21

 

0.049

-1154G/A (rs 1570360)

   AA

57 (11.6 %)

51 (10.3%)

1.00 (ref.)

17 (16.0%)

1.00 (ref.)

33 (8.8%)

1.00 (ref.)

   AG

227 (46.1%)

208 (42.0%)

1.01 (0.66–1.55)

48 (45.3%)

0.66 (0.34–1.25)

152 (40.5%)

1.14 (0.70–1.84)

   GG

208 (42.3%)

236 (47.7%)

1.29 (0.84–1.97)

41 (38.7%)

0.62 (0.32–1.20)

190 (50.7%)

1.64 (1.02–2.64)

   P (for trend)

  

0.083

 

0.24

 

0.007

-634G/C (rs 201963)

   GG

232 (46.4 %)

221 (44.7%)

1.00 (ref.)

56 (52.8%)

1.00 (ref.)

161 (42.9%)

1.00 (ref.)

   CG

221 (44.2%)

222 (44.9%)

1.05 (0.80–1.37)

39 (36.8%)

0.73 (0.46–1.15)

174 (46.4%)

1.13 (0.85–1.50)

   CC

47 (9.4%)

52 (10.5%)

1.18 (0.76–1.83)

11 (10.4%)

0.88 (0.42–1.84)

40 (10.7%)

1.27 (0.79–2.05)

   P (for trend)

  

0.47

 

0.35

 

0.26

+936C/T (rs 3025039)

   TT or CTb

126 (26.3%)

128 (26.2%)

1.00 (ref.)

39 (38.2%)

1.00 (ref.)

86 (23.1%)

1.00 (ref.)

   CC

353 (73.7%)

360 (73.8%)

1.02 (0.76–1.36)

63 (61.8%)

0.59 (0.37–0.93)

286 (76.9%)

1.21 (0.88–1.67)

   P (for trend)

  

0.73

 

0.052

 

0.20

Blood prediction scorec

   0–1

31 (6.5 %)

38 (7.8 %)

1.00 (ref.)

11 (10.9 %)

1.00 (ref.)

27 (7.3 %)

1.00 (ref.)

   2

157 (33.0%)

131 (27.0%)

0.72 (0.42–1.22)

38 (37.6%)

0.75 (0.34–1.64)

90 (24.3%)

0.68 (0.38–1.22)

   3

198 (41.6%)

214 (44.1%)

0.92 (0.55–1.55)

39 (38.6%)

0.56 (0.25–1.24)

166 (44.7%)

0.99 (0.57–1.75)

   4

90 (18.9%)

102 (21.0%)

0.99 (0.57–1.72)

13 (12.9%)

0.39 (0.15–0.98)

88 (23.7%)

1.22 (0.67–2.23)

   Trend OR (95% CI)d

  

1.09 (0.94–1.26)

 

0.73 (0.57–0.96)

 

1.20 (1.02–1.41)

   P (for trend)

  

0.28

 

0.021

 

0.030

  1. Odds ratios (ORs) are adjusted for birth-year, year of blood draw, and race/ethnicity. aIncludes 14 cases of unknown stage. bThe TT genotype was carried by eight controls and six cases (two in situ cases and four invasive cases). cSum of -2578C and +936C alleles, which have each been associated with increased blood levels of vascular endothelial growth factor. dOR associated with a 1-point increase in the blood prediction score. CI, confidence interval;
Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us